Skip to content

Type 2 diabetes — guidelines

TL;DR — Major guidelines now select therapy by cardiovascular, heart-failure, kidney and weight benefit as well as HbA1c. ADA/EASD 2022 recommends SGLT2 inhibitors or GLP-1RA for organ protection in appropriate high-risk patients independent of metformin and baseline HbA1c (Davies 2022, PMID 36148880). ADA updates annually; NICE NG28 was materially updated in February 2026 and now offers metformin plus an SGLT2 inhibitor even without a relevant comorbidity. KDIGO places SGLT2 therapy, renin–angiotensin-system blockade when indicated and layered cardiorenal care at the centre of diabetes with CKD. Differences reflect evidence dates, health-system economics and scope, not only scientific disagreement.

Current documents

Body Document Region Live status/source
ADA Standards of Care in Diabetes—2026 US/global influence Annual; current (ADA 2026, PMID 41358900; PMID 41358899)
ADA/EASD Management of Hyperglycaemia 2022 consensus International Current consensus (Davies 2022, PMID 36148880)
NICE NG28 Type 2 diabetes in adults England/Wales Updated 18 Feb 2026 (NICE NG28, accessed 2026-08-30)
KDIGO Diabetes Management in CKD 2022 International 2022 current; 2026 draft under public review (KDIGO, accessed 2026-08-30)
WHO Pharmacological treatment guidance Global/resource-sensitive Emphasises essential, scalable treatment

Shared architecture

Clinical state Broad convergence
Established ASCVD/high risk GLP-1RA and/or SGLT2 with demonstrated benefit
Heart failure SGLT2 inhibitor prioritised
CKD SGLT2 foundational when eligible; layered kidney protection
Need major weight loss GLP-1RA/dual agonist or metabolic intervention
Catabolic symptoms/severe hyperglycaemia Insulin considered promptly
Hypoglycaemia vulnerability Avoid/deintensify insulin secretagogues and excess insulin
Cost constraint Use effective affordable agents while preserving safety

HbA1c targets

ADA states <7% is appropriate for many nonpregnant adults, with lower targets for low-risk individuals and less stringent targets for frailty, severe comorbidity or high treatment burden. NICE supports 6.5% for diet or non-hypoglycaemia regimens and 7.0% for hypoglycaemia-associated medicines, with individual relaxation (NICE NG28, accessed 2026-08-30).

Dimension ADA framing NICE framing
Default <7% for many 6.5% or 7.0% depending regimen
Individualisation Benefit, hypoglycaemia, burden, function Shared target; relax for frailty/comorbidity/risk
Monitoring HbA1c/CGM as appropriate 3–6 monthly until stable, then 6 monthly
Invalid HbA1c Use glucose alternatives Plasma profiles/fructosamine alternatives

Medication sequencing disagreements

NICE 2026 recommends modified-release metformin plus an SGLT2 inhibitor for adults with no relevant comorbidity, a more universal initial SGLT2 position than older glucose-first algorithms. ADA/EASD allows initial combination and prioritises organ-risk phenotype; no single sequence fits all (Davies 2022, PMID 36148880).

Tension Why guidance differs
Metformin-first vs organ-protection-first Trial evidence, price and formulary assumptions
GLP-1RA before insulin Weight/hypoglycaemia advantage vs catabolic urgency
HbA1c threshold for intensification Population benefit vs individual burden
CGM in T2D Insulin intensity, evidence and reimbursement
Surgery eligibility BMI thresholds, capacity and long-term follow-up

CKD layering

KDIGO 2022 integrates lifestyle, ACE inhibitor/ARB for hypertension with albuminuria, SGLT2 therapy, statins, finerenone for selected persistent albuminuria and GLP-1RA where further glucose/weight/CV benefit is required. On 2026-08-30, KDIGO's live page listed a 2026 draft update under public review; draft recommendations are not treated as final guidance (KDIGO, accessed 2026-08-30). FLOW strengthens the GLP-1 kidney layer (Perkovic 2024, PMID 38785209).

Evidence versus recommendation

Guideline classes are not interchangeable. A recommendation may incorporate patient preference, cost, feasibility and equity beyond RCT effect size. Conversely, rapid annual updates can rely on surrogate endpoints or expert consensus where direct trials are absent.

Cross-guideline decision matrix

Decision ADA/ADA-EASD NICE 2026 KDIGO 2022 IDF 2025
No comorbidity, initial drug Individualised; metformin common Metformin MR + SGLT2 Outside primary scope Optimal/basic-care stratified
Established ASCVD GLP-1RA/SGLT2 with benefit Comorbidity-specific pathway Layer CV/kidney protection Organ-risk approach
Heart failure SGLT2 priority SGLT2 pathway SGLT2 foundational SGLT2 where accessible
CKD SGLT2; GLP-1/finerenone layers eGFR/comorbidity pathway Detailed layered algorithm Cardiorenal chapter
Major weight goal High-efficacy incretin/surgery GLP-1/tirzepatide eligibility GLP-1 as additional therapy Weight-control chapter
Severe symptoms/catabolism Insulin Consider insulin Acute stabilisation Insulin in decompensation
Cost barrier Explicit access discussion NHS cost-effectiveness/formulary Resource implementation Basic-care alternative

Prevention and screening differences

Issue Difference
Fasting “prediabetes” lower bound ADA 100 mg/dL; WHO/IDF comparison uses 110 mg/dL
HbA1c prediabetes ADA 5.7–6.4%; WHO does not define the same category
Screening age/risk Country prevalence and resource assumptions differ
Metformin prevention More explicit in US high-risk care than some public-health documents

These definitional differences change the number labelled high risk and the apparent conversion rate. They are policy choices layered on continuous biology, not evidence of two different diseases.

Guideline quality checklist

  • Is the evidence search date explicit?
  • Are conflicts of interest disclosed and managed?
  • Are recommendation strength and evidence certainty separated?
  • Are absolute effects given for different baseline risks?
  • Were people living with T2D included in panel decisions?
  • Are resource and equity effects explicit?
  • Is there an update mechanism after landmark trials?
  • Are implementation metrics defined?

Implementation measures

Recommendation Auditable measure
SGLT2 in eligible CKD/HF Eligible proportion prescribed or contraindication documented
Eye/foot/kidney surveillance Completion within specified interval
Individualised HbA1c Target and rationale recorded
Hypoglycaemia reduction Severe events and deintensification review
Shared decision-making Preference/cost discussion documented
Remission follow-up Annual HbA1c and complication surveillance

Supersession discipline

Older recommendations should remain discoverable with explicit chains. The 2017 IDF primary-care document is superseded by IDF 2025; older NICE medication recommendations are superseded within NG28 by the February 2026 update. See the registry for dated status.

Research-use caution

Guidelines synthesise evidence for decisions; they are not substitutes for trial reports when quoting effect sizes. This page cites recommendations, while numerical efficacy and safety claims remain anchored to the original PubMed-verified trials.

Update triggers

Trigger Required response
New hard-outcome RCT Reassess recommendation and certainty
Safety warning Update contraindications and monitoring
Generic entry/price shift Recalculate access and cost-effectiveness
New device evidence Reassess eligible monitoring population
Guideline supersession Preserve old record with explicit chain
Major implementation failure Test a simpler delivery strategy

The ADA’s diagnosis, microvascular-care and annual revision modules illustrate why a guideline suite must be read across sections rather than as a drug algorithm alone (ADA 2026, PMID 41358893; PMID 41358886; PMID 41358896).

Cross-domain evidence crosswalk

These adjacent studies constrain interpretation of this page and make explicit where its conclusions depend on prevention, organ-outcome, remission, burden or implementation evidence.

Verified evidence anchor Connection
(Zinman 2015, PMID 26378978) Zinman B, et al. Empagliflozin Cardiovascular Outcomes. N Engl J Med. 2015
(Marso 2016, PMID 27295427) Marso SP, et al. Liraglutide Cardiovascular Outcomes. N Engl J Med. 2016
(Marso 2016, PMID 27633186) Marso SP, et al. Semaglutide Cardiovascular Outcomes. N Engl J Med. 2016
(Perkovic 2019, PMID 30990260) Perkovic V, et al. Canagliflozin Renal Outcomes. N Engl J Med. 2019
(Gerstein 2019, PMID 31189511) Gerstein HC, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes. Lancet. 2019;394:121-130
(Wiviott 2019, PMID 30415602) Wiviott SD, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019
(Heerspink 2020, PMID 32970396) Heerspink HJL, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020
(EMPA-KIDNEY 2023, PMID 36331190) EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023
(Holman 2008, PMID 18784090) Holman RR, et al. 10-year follow-up of intensive glucose control. N Engl J Med. 2008;359:1577-1589
(Adler 2024, PMID 38772405) Adler AI, et al. UKPDS 91: 24-year post-trial monitoring. Lancet. 2024;404:145-155
(Lean 2018, PMID 29221645) Lean MEJ, et al. Primary care-led weight management for remission. Lancet. 2018
(Lean 2024, PMID 38423026) Lean MEJ, et al. Five-year follow-up of DiRECT. Lancet Diabetes Endocrinol. 2024
(TODAY 2021, PMID 34320286) TODAY Study Group. Long-Term Complications in Youth-Onset Type 2 Diabetes. N Engl J Med. 2021
(Speight 2024, PMID 38128969) Speight J, et al. Bringing an end to diabetes stigma and discrimination: an international consensus statement on evidence and recommendations. Lancet Diabetes Endocrinol. 2024
(Palmer 2021, PMID 33441402) Palmer SC, et al. SGLT2 inhibitors and GLP-1RA network meta-analysis. BMJ. 2021
(UKPDS 1998, PMID 9742976) UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin (UKPDS 33). Lancet. 1998

Additional guideline positions and their evidence frames

Body/document Position emphasised Evidence frame Tension with other guidance
ACP newer medicines 2024 Add SGLT2 inhibitor or GLP-1 agonist to metformin/lifestyle when control inadequate; recommend against DPP-4 addition for morbidity/mortality reduction Strong recommendations, high-certainty evidence (Qaseem 2024, PMID 38639546) More explicitly metformin-first and outcome-threshold focused than phenotype-first algorithms
KDIGO 2022 synopsis Layer lifestyle/self-management, SGLT2, then GLP-1RA and/or nonsteroidal MRA with BP/lipid/glycaemia care 13 recommendations and 52 practice points; kidney-function preservation is organising goal (Navaneethan 2023, PMID 36623286) Applies specifically to CKD; cannot be generalised to low-risk T2D
AACE 2022/2023 Complication-centric and glucose-centric algorithms; obesity treatment and access/cost as explicit pillars 170 evidence-based recommendations plus consensus visual algorithm (Blonde 2022, PMID 35963508; Samson 2023, PMID 37150579) Greater algorithmic breadth; many branches rely on consensus rather than direct strategy trials
ESC 2023 Cardiovascular risk and disease drive integrated diabetes/CVD management European cardiology guideline (Marx 2023, PMID 37622663) Cardiology lens can prioritise organ protection over glycaemic sequencing
ACP HbA1c guidance 2018 Aim 7%–8% for most; consider deintensifying below 6.5%; symptom focus with limited life expectancy Synthesis of six guidelines using AGREE II (Qaseem 2018, PMID 29507945) Broader/less intensive than ADA/AACE targets for many healthy adults

The ACP target controversy illustrates why a target cannot be separated from intervention. An HbA1c of 6.4% achieved with weight loss or low-hypoglycaemia therapy has a different harm profile from the same value achieved using insulin/sulfonylurea in frailty. ADA/AACE favour individualisation around achievable benefit; ACP more explicitly defaults most adults to 7%–8%. Neither position is a randomised comparison of guideline strategies.

From evidence to recommendation: where divergence enters

Translation step Source of divergence
Outcome selection MACE, HF, kidney failure, HbA1c, weight, adverse events and cost receive different priority
Baseline risk Relative effects yield very different absolute benefits in established disease vs primary prevention
Comparator Placebo CVOTs answer addition; active-comparator trials answer sequencing
Certainty threshold Guideline panels differ on indirect networks, subgroup interactions and surrogate outcomes
Resource assumption WHO/basic-care approaches optimise feasible coverage; ADA/EASD/AACE assume broader availability
Time horizon Short glycaemic effects, 2–5-year organ outcomes and decades-long legacy benefits compete
Patient preference Route, adverse effects, monitoring, weight and cost can reverse the ranking for an individual

The ACP evidence review covered 84 RCTs and found SGLT2 inhibitors and GLP-1 agonists reduced all-cause mortality and MACE versus usual care; SGLT2 inhibitors reduced CKD progression/HF admissions and GLP-1 agonists reduced stroke. Yet predefined minimally important differences were not met for several relative benefits and direct drug comparisons were sparse (Drake 2024, PMID 38639549). This explains how panels can review overlapping evidence and issue different sequencing recommendations without either misreading the trials.

Explicit unresolved disagreements

  • Metformin prerequisite: ACP frames addition to metformin; ADA/EASD and organ-specific guidance allow SGLT2/GLP-1 treatment independent of metformin in relevant disease.
  • Default HbA1c: ACP 7%–8% for most versus lower targets often favoured for healthy adults by ADA/AACE, with all groups endorsing individualisation.
  • DPP-4 inhibitors: glycaemic safety and tolerability remain useful, but ACP recommends against adding them for morbidity/mortality reduction (Qaseem 2024, PMID 38639546).
  • Combination organ protection: KDIGO layers classes; hard-outcome incremental randomisation of SGLT2 plus GLP-1 remains limited.
  • Resource-sensitive sequencing: older WHO guidance prioritises affordable sulfonylurea/insulin; high-resource guidelines prioritise organ outcomes.

Open questions

  • Which cross-guideline differences cause measurable outcome differences rather than documentation differences?
  • Should combination SGLT2+GLP-1 therapy become default for dual-risk patients before direct combination outcome trials?
  • How should guideline panels incorporate drug scarcity and global affordability? (Sun 2022, PMID 34879977)
  • Can living guidelines keep recommendations current while preserving transparent evidence review? (Agarwal 2025, PMID 40813129)

References

  1. Davies MJ, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. Diabetes Care. 2022. PMID 36148880
  2. ADA Professional Practice Committee. Pharmacologic Approaches to Glycemic Treatment: Standards of Care-2026. Diabetes Care. 2026. PMID 41358900
  3. ADA Professional Practice Committee. Cardiovascular Disease and Risk Management: Standards of Care-2026. Diabetes Care. 2026. PMID 41358899
  4. ADA Professional Practice Committee. Diagnosis and Classification: Standards of Care-2026. Diabetes Care. 2026. PMID 41358893
  5. ADA Professional Practice Committee. Retinopathy, Neuropathy, and Foot Care-2026. Diabetes Care. 2026. PMID 41358886
  6. ADA Professional Practice Committee. Summary of Revisions: Standards of Care-2026. Diabetes Care. 2026. PMID 41358896
  7. Perkovic V, et al. Semaglutide on CKD in T2D. N Engl J Med. 2024. PMID 38785209
  8. Agarwal A, et al. Living guideline for T2D therapeutics. BMJ. 2025. PMID 40813129
  9. Sun H, et al. IDF Diabetes Atlas prevalence estimates. Diabetes Res Clin Pract. 2022. PMID 34879977
  10. Zinman B, et al. Empagliflozin Cardiovascular Outcomes. N Engl J Med. 2015. PMID 26378978
  11. Marso SP, et al. Liraglutide Cardiovascular Outcomes. N Engl J Med. 2016. PMID 27295427
  12. Marso SP, et al. Semaglutide Cardiovascular Outcomes. N Engl J Med. 2016. PMID 27633186
  13. Perkovic V, et al. Canagliflozin Renal Outcomes. N Engl J Med. 2019. PMID 30990260
  14. Gerstein HC, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes. Lancet. 2019;394:121-130. PMID 31189511
  15. Wiviott SD, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019. PMID 30415602
  16. Heerspink HJL, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020. PMID 32970396
  17. EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023;388:117-127. PMID 36331190
  18. Holman RR, et al. 10-year follow-up of intensive glucose control. N Engl J Med. 2008;359:1577-1589. PMID 18784090
  19. Adler AI, et al. UKPDS 91: 24-year post-trial monitoring. Lancet. 2024;404:145-155. PMID 38772405
  20. Lean MEJ, et al. Primary care-led weight management for remission. Lancet. 2018. PMID 29221645
  21. Lean MEJ, et al. Five-year follow-up of DiRECT. Lancet Diabetes Endocrinol. 2024. PMID 38423026
  22. TODAY Study Group. Long-Term Complications in Youth-Onset Type 2 Diabetes. N Engl J Med. 2021. PMID 34320286
  23. Speight J, et al. Bringing an end to diabetes stigma and discrimination: an international consensus statement on evidence and recommendations. Lancet Diabetes Endocrinol. 2024. PMID 38128969
  24. Palmer SC, et al. SGLT2 inhibitors and GLP-1RA network meta-analysis. BMJ. 2021. PMID 33441402
  25. UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin (UKPDS 33). Lancet. 1998. PMID 9742976
  26. Qaseem A, et al. Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: ACP Guideline. Ann Intern Med. 2024;177:658-666. PMID 38639546
  27. Drake T, et al. Newer Pharmacologic Treatments: Systematic Review and Network Meta-analysis. Ann Intern Med. 2024;177:618-632. PMID 38639549
  28. Navaneethan SD, et al. Diabetes Management in CKD: Synopsis of KDIGO 2022. Ann Intern Med. 2023;176:381-387. PMID 36623286
  29. Blonde L, et al. AACE Clinical Practice Guideline: Comprehensive Care Plan—2022 Update. Endocr Pract. 2022;28:923-1049. PMID 35963508
  30. Samson SL, et al. AACE Comprehensive Type 2 Diabetes Management Algorithm—2023 Update. Endocr Pract. 2023;29:305-340. PMID 37150579
  31. Marx N, et al. 2023 ESC Guidelines for cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44:4043-4140. PMID 37622663
  32. Qaseem A, et al. Hemoglobin A1c Targets for Glycemic Control: ACP Guidance Statement. Ann Intern Med. 2018;168:569-576. PMID 29507945